maintenance therapy

Type: Keyphrase
Name: maintenance therapy
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance [Global Data Point]

Interim Report First Half 2014?Announced three new Phase III studies of daratumumab in multiple myeloma and improved guidance twice?Achieved USD 25 million milestone payment under Janssen Biotech, Inc. collaboration for daratumumab?Arzerra (ofatumumab) ... [Published Pharmacy Choice - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance

; Copenhagen, Denmark;"We continue to make solid progress across our business as the year progresses. The label expansion for Arzerra to include treatment of first-line patients with CLL in the US in combination with chlorambucil in April was followed ... [Published Noodls - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Ambit Biosciences Announces Second Quarter 2014 Operating Results

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results ... [Published Bio-Medicine - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

[Articles] Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

Significant clinical benefit was seen at week 16 that increased with maintenance therapy. ... [Published The Lancet online - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Genmab announces positive interim result from Phase III CLL study analysis

GlaxoSmithKline plc, or GSK, and Genmab A/S, a biotechnology company, have announced that an Independent Data Monitoring Committee, or IDMC, interim analysis of a Phase III study, PROLONG, reached the predefined significance level for efficacy. The interim ... [Published Individual.com - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

The cost-effectiveness of treatment for opioid dependency

The following originally appeared on  The Upshot  (copyright 2014, The New York Times Company). Once  championed as the answer to chronic pain , opioid medications and painkillers have become a large and costly problem in the United States. Fatal overdoses ... [Published The Incidental Economist (Posts) - Aug 06 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody

The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in ... [Published Free Patents Online - Aug 05 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 2 reports

GlaxoSmithKline and Genmab report positive data from CLL drug trial

:07 in Pharmaceutical Company Product News GlaxoSmithKline and Genmab have announced that their drug ofatumumab has met its primary endpoint in a new efficacy trial for chronic lymphocytic leukaemia (CLL). An independent data monitoring committee has ... [Published Zenopa - Aug 05 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Positive Phase III Results Reported for Ofatumumab (Arzerra) as Maintenance Therapy for Relapsed CLL

Treatment achieves significance level for efficacyAccording to an independent data monitoring committee (IDMC) interim analysis, the phase III PROLONG trial has reached the predefined significance level for efficacy ( P ≤ 0.001).The interim analysis demonstrated ... [Published PT Community - Aug 01 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

FDA approves COPD once-daily maintenance therapy

FDA has approved Striverdi Respimat (olodaterol) inhalation spray for the treatment of chronic obstructive pulmonary disease (COPD). The long-acting beta-adrenergic agonist (LABA) by Boehringer Ingelheim Pharmaceuticals can be used once daily as maintenance ... [Published Drugtopics.com - Aug 01 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Citigroup Inc. Quarterly Report for the period ended June 30, 2014

1[Iliad Press Release] Iliad confirms its interest in T-Mobile US2GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL3L'Oréal: News Release: "First-half 2014 results"4Ashland Inc. reports ... [Published EuroInvestor - Aug 01 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 6 reports

GSK and Genmab announce positive interim results for ofatumumab Phase III

UK Pharma major GlaxoSmithKline (LSE: GSK) and Danish biotechnology company Genmab (OMX: GEN) have said that an interim analysis of a Phase III study of ofatumumab met predefined levels to prove its efficacy.The analysis demonstrated that treating chronic ... [Published Pharma Letter - Aug 01 2014]

Quotes

...However, as a result of the fact that fewer patients receive terminal diagnosis it is not an attractive area for research," Dr. Bunimovich said. "The quality of life during treatment however is unbearable, and the patient is often required to undergo surgery and many rounds of chemotherapy."
...QUANTUM-R PhasePhase 3 trial, our most notable achievement of the first half," said Michael Martino, Ambit's President and Chief Executive Officer. "The trial is progressing and sites continue to be activated on plan. This will remain our primary operating focus throughout the year. We are also pleased with the progress in multiple investigator- and company-sponsored studies that continue to suggest that quizartinib may be a workhorse in the broader fight against AML in newly diagnosed patients and as a maintenance therapy in patients after transplant. With QUANTUM-R underway, we are taking the next steps to execute this broader vision for quizartinib."
?Improved operating result by DKK 54 million over H1 2013 "We continue to make solid progress across our business as the year progresses. The label expansion for Arzerra to include treatment of first-line patients with CLL in the US in combination with chlorambucil in April was followed closely by approval in Europe for Arzerra in combination with chlorambucil or bendamustine. We were pleased to announce that the Phase III study of ofatumumab as maintenance therapy in relapsed CLL met its primary endpoint at an interim analysis. Furthermore, we announced three new Phase III studies of daratumumab in combination with backbone therapies, one in relapsed or refractory multiple myeloma and two in first line multiple myeloma. In July we reached a USD 25 million milestone based on progress in the first Phase III study under our collaboration with Janssen and have again been able to improve our financial guidance" said Jan van de Winkel, Ph D , Chief Executive Officer of Genmab
"Optionally, the anchoring unit foreshortens upon deployment of said device in the intestinal wall or smooth muscles to pull the device deeper into said intestinal wall or smooth muscles. Upon deployment of said device into an implant site, a shape of said anchoring unit changes to a predetermined shape, said predetermined shape being determined according to the implant site. The shape of said anchoring unit changes to any one of a T-bar, a ship anchor, a spiral disc, a hook, a club, a spiral loop, a loop or any freeform shape capable of anchoring."

More Content

All (108) | News (93) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Swiss researchers investigate drug use and its ... [Published CATIE - 4 hours ago]
Addiction and survival with HIV [Published CATIE - Aug 26 2014]
Data on Celgene's Revlimid Published in Oncolog... [Published Yahoo! Finance - Aug 22 2014]
Metastatic Colorectal Cancer: Update Now Shows ... [Published Oncology Times - Aug 22 2014]
Woman's Cancer Drives Daughter To Research Brea... [Published Virtual Jerusalem - Aug 21 2014]
No Tumor-Free Waiting Period after Treatment of... [Published Sexual Development - Aug 21 2014]
Anti-infliximab antibodies associated with trea... [Published Orthopedics Today - Aug 19 2014]
Carcinoma of Unknown Primary Site Treated with ... [Published Sexual Development - Aug 19 2014]
Ambit Biosciences Releases 2Q 2014 Results [Published Individual.com - Aug 18 2014]
What is the correct diagnosis and how should it... [Published Medicine Today - Aug 17 2014]
A Pharmacogenetics-Based Warfarin Maintenance D... [Published Plosone.org - Aug 16 2014]
Selected Patients With Lung Cancer and Poor Per... [Published The ASCO Post - Aug 15 2014]
Periodontal disease starts painlessly, so don’t... [Published Community Voice - Aug 15 2014]
Genmab Announces Financial Results for the Firs... [Published Pharmacy Choice - Aug 14 2014]
Predicting Resistance by Selection of Signaling... [Published General Medicine eJournal - Aug 14 2014]
Genmab's (GNMSF) CEO Jan Winkel on Q2 2014 Resu... [Published Seeking Alpha - Aug 14 2014]
Patent Issued for Device and Implantation Syste... [Published 4 Traders - Aug 14 2014]
Genmab Announces Financial Results for the Firs... [Published Noodls - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published Virtual Strategy Magazine - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published SPi World News - Aug 13 2014]
Genmab Announces Financial Results for the Firs... [Published GlobeNewswire: Acquisitions News - Aug 13 2014]
Ambit Biosciences' (AMBI) CEO Mike Martino on Q... [Published Seeking Alpha - Aug 13 2014]
Ambit Biosciences Announces Second Quarter 2014... [Published Bio-Medicine - Aug 12 2014]
Lymphoma: New Data on PET-CT's Predictive Abili... [Published Oncology Times - Aug 12 2014]
Questions and Answers About Neurostimulation an... [Published Newswise - Aug 12 2014]
[Articles] Oral ponesimod in patients with chro... [Published The Lancet online - Aug 11 2014]
Addicts need compassion — and treatment [Commen... [Published Baltimore Sun - Aug 08 2014]
Genmab announces positive interim result from P... [Published Individual.com - Aug 08 2014]
Mayo Clinic Health Letter: Highlights from the ... [Published Mayo Clinic College of Medicine - Aug 08 2014]
Combination regimen safe, effective in treatmen... [Published Orthopedics Today - Aug 08 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Articles] Oral ponesimod in patients with chro... [Published The Lancet online - Aug 11 2014]
Significant clinical benefit was seen at week 16 that increased with maintenance therapy. ...
The cost-effectiveness of treatment for opioid ... [Published The Incidental Economist (Posts) - Aug 06 2014]
The following originally appeared on  The Upshot  (copyright 2014, The New York Times Company). Once  championed as the answer to chronic pain , opioid medications and painkillers have become a large and costly problem in the United States. Fatal overdoses ...
BiologicTx® Selected As The Specialty Pharmacy ... [Published PR Newswire: Health - Jul 17 2014]
TOTOWA, N.J., July 17, 2014 /PRNewswire/ -- BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on ...
RheumShorts: Vasculitis, MRI, Anakinra for Knee... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 29 2014]
(MedPage Today) -- The rheumatology literature this week explored whether or not patients with vasculitis treated with rituximab also need maintenance therapy, if MRI can predict later arthritis when disease is still subclinical, and how an interleukin ...
Orexo: Positive Top-Line Results from Two Phase... [Published Business Wire Health News - Jun 23 2014]
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX) Orexo AB (publ) announces the results of two clinical trials assessing Zubsolv for induction of buprenorphine maintenance therapy in patients with opioid dependence. Combined data from ...
1 2 3

Press Releases

sort by: Date | Relevance
Genmab Announces Financial Results for the Firs... [Published GlobeNewswire: Acquisitions News - Aug 13 2014]
Positive Top-line Results from Two Phase 3 Clin... [Published GlobeNewswire: Advertising News - Jun 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.